1: Kreckler L, Osinski M, Williams S, Whiting R. Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D2/D3 Selective Receptor Antagonist for the Management of Gastroparesis. J Exp Pharmacol. 2022 Feb 9;14:43-57. doi: 10.2147/JEP.S332715. PMID: 35173492; PMCID: PMC8842350.
2: Yamaguchi T, Kudou K, Okamoto H, Chen C, Whiting R, Sekino H. Evaluating the Safety, Tolerability, and Disposition of Trazpiroben, a D2 /D3 Receptor Antagonist: Phase I Single- and Multiple-Ascending Dose Studies in Healthy Japanese Participants. Clin Pharmacol Drug Dev. 2021 Dec 29. doi: 10.1002/cpdd.1057. Epub ahead of print. PMID: 34967147.
3: Chen C, Zhang W, Bari M, Almansa C, Baratta M, Rosario M. Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D2/D3 Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor. Clin Pharmacol. 2021 Jul 12;13:145-155. doi: 10.2147/CPAA.S310609. PMID: 34285598; PMCID: PMC8285519.
4: Whiting RL, Choppin A, Luehr G, Jasper JR. Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D2/D3 Receptor Antagonist for the Management of Gastroparesis. J Pharmacol Exp Ther. 2021 Oct;379(1):85-95. doi: 10.1124/jpet.121.000698. Epub 2021 Jul 12. PMID: 34253646.
5: Kuo B, Scimia C, Dukes G, Zhang W, Gupta S, Chen C, Chuang E, Camilleri M. Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D2 /D3 receptor antagonist, in patients with gastroparesis. Aliment Pharmacol Ther. 2021 Aug;54(3):267-280. doi: 10.1111/apt.16451. Epub 2021 Jun 20. PMID: 34148244.
6: Nishihara M, Ramsden D, Balani SK. Evaluation of the drug-drug interaction potential for trazpiroben (TAK-906), a D2/D3 receptor antagonist for gastroparesis, towards cytochrome P450s and transporters. Xenobiotica. 2021 Jun;51(6):668-679. doi: 10.1080/00498254.2021.1912438. Epub 2021 Apr 21. PMID: 33879032.
7: Whiting RL, Darpo B, Chen C, Fletcher M, Combs D, Xue H, Stoltz RR. Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D2 /D3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Aug;10(8):927-939. doi: 10.1002/cpdd.906. Epub 2021 Jan 18. PMID: 33462988; PMCID: PMC8451790.